Barinthus Biotherapeutics (BRNS) Net Cash Flow (2020 - 2026)

Barinthus Biotherapeutics has reported Net Cash Flow for 7 years, with the latest figure at -$3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 77.79% year-over-year to -$3.3 million; the trailing twelve-month figure through Mar 2026 stood at -$36.0 million (down 16.22% YoY), and the FY2025 full-year result was -$47.6 million, down 71.89% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$3.3 million, up from -$4.2 million in the prior quarter.
• The five-year high for Net Cash Flow was $13.6 million in Q4 2024, with the low at -$20.0 million in Q2 2023.
• Historically, Net Cash Flow has averaged -$9.0 million across 5 years, with a median of -$11.2 million in 2023.
• Annual changes were most pronounced in 2022 — Net Cash Flow surged 379.25% — and 2023, when it slumped 213.33%.
• Barinthus Biotherapeutics' Net Cash Flow stood at -$11.4 million in 2022, then plunged by 68.99% to -$19.3 million in 2023, then jumped by 170.55% to $13.6 million in 2024, then tumbled by 131.07% to -$4.2 million in 2025, then climbed by 21.91% to -$3.3 million in 2026.
• The last three Net Cash Flow figures came in at -$3.3 million (Q1 2026), -$4.2 million (Q4 2025), and -$10.3 million (Q3 2025), per Business Quant data.